

On page 16, line 22, please replace "Hevac" with --HEVAC--.  
On page 17, line 22, please replace "Sephadex" with --SEPHADEX--.  
On page 19, line 13, please replace "centriprep-10" with --CENTRIPREP-10--.  
On page 19, line 19, please replace "Sephadex" with --SEPHADEX--.  
On page 20, line 7, please replace "Pharmalink" with --PHARMALINK--.  
On page 20, line 24, please replace "Emax" with --EMAX--.  
On page 20, line 24, please replace "SoftMax" with --SOFTMAX--.  
On page 21, line 8, please replace "FACScan" with --FACSCAN--.  
On page 27, line 22, please replace "Plate Wash" with --PLATE WASH, a wash,--.  
After page 31, please insert the enclosed Sequence Listing as the new page 31, and renumber the remaining pages thereafter to be consecutive.

On the new page 32, the Sequence Listing, please update the "current application data" to recite the current application Serial No. 08/630,383. Additionally, please replace the "addressee" and "attorney name" with "Richard F. Trecartin, Registration No. 31,801."

**In the claims:**

Please amend the claims as follows:

1. (Amended) A method for killing a target cell in a mammalian host comprising said target cell and an endogenous cytotoxic effector system comprising a least one effector agent, said method comprising:

introducing a conjugate into said host in sufficient amount to kill the target cells, wherein said conjugate is characterized by comprising a moiety other than an antibody specific for a surface protein joined to a selective moiety capable of binding to said effector system to form a cell killing complex, with the proviso that when said selective moiety binds to a T-cell, (a) it binds to the T-cell receptor and (b) said moiety specific for a surface protein is a ligand;

wherein said effector system comprises (1) antibodies specific for said selective moiety and an antibody dependent cytotoxic system comprising at least one effector agent

or (2) a T-cell, whereby when said conjugate is bound to both of said target cell and said effector agent, said cell is killed.

2. (Amended) A method according to Claim 1, wherein said selective moiety is a blood group antigen, [xenoantigen] ~~an antigen foreign to said mammalian host~~ to which antibodies are present in said mammalian host or a superantigen.

G1

3. (Amended) A method according to Claim 2, wherein said selective moiety is a superantigen selected from the group consisting of SEC1, SEA, SEB, ExFT, TSST1, [Mis] MIs, or minor histocompatibility antigen.

504 B1

6. (Amended) A method according to Claim 1, wherein said [selective] moiety specific for a surface protein is a low molecular weight binding molecule, wherein said molecular weight is between about 100 to about 5000 daltons.

504 B2  
92

8. (Amended) A method according to Claim [6] 7, wherein said ligand is IL-

93

2.

10. (Amended) A method according to Claim [8] 9, wherein said cytokine is [a] an interleukin.

C

11. (Amended) A method according to Claim [9] 10, wherein said interleukin is IL-2.

94